|
|
|
| home > ebr > winter 2022 > understanding the bottlenecks holding back biologics |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
EBR: How has biologics production developed in recent years?
Alex Page: Prior to the pandemic, the answer to this question was fairly straightforward. Most of the focus was on developing continuous processing to improve downstream throughput, as well as the move towards ‘scaling out’ instead of ‘scaling up’ to help reduce risk and increase flexibility of production space.
While those concepts are still a critical element of most continuous improvement strategies in the industry, messenger RNA (mRNA) therapies have become a dominant subject whenever the future of biologics production is discussed. The previously unfathomable speed of highly efficacious mRNA COVID-19 vaccines, from discovery to approval, has shown the industry what is possible with this relatively new technology. The fallout of this will certainly have a significant effect on virtually every aspect of drug development, clinical trials, and commercialisation moving forwards. One of the most inspiring developments
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Emmes Rapidly Expands in India – Driven By Deep Vaccines and Infectious Diseases Expertise and Enhanced Study Startup Capabilities
Global CRO’s India office reports surging growth from Western, regional and local trial customers
More info >> |
|
 |
White Papers |
 |
|
|
